| Jumlah Saham Beredar | 1,261,290 shares |
| Saham Orang Dalam | 622,454 shares |
| Kepemilikan oleh Orang Dalam | 49.35 % |
| Orang Dalam Sejati | 20 |
Skor Sentimen Orang Dalam
Skor Sentimen Orang Dalam mengidentifikasi perusahaan yang dibeli oleh orang dalam korporat.
Ini adalah hasil dari model kuantitatif multifaktor yang canggih yang mengidentifikasi perusahaan dengan tingkat akumulasi internal tertinggi. Model penilaian ini menggunakan kombinasi dari jumlah bersih orang dalam yang membeli dalam 90 hari sebelumnya, total saham yang dibeli sebagai persentase dari jumlah saham yang beredar, dan total saham yang dimiliki oleh orang dalam. Angka tersebut berkisar dari 0 hingga 100, dengan angka yang lebih tinggi menunjukkan tingkat akumulasi yang lebih tinggi dibandingkan dengan perusahaan sejenis, dan 50 adalah rata-rata.
Frekuensi Pembaruan: Setiap Hari
Skor Sentimen Petugas
Skor Sentimen Pejabat menemukan perusahaan yang dibeli oleh Pejabat Korporat.
Menurut definisi, Pejabat Korporasi adalah Orang Dalam Korporasi, tetapi tidak seperti beberapa Orang Dalam lainnya (Pemegang Saham 10% dan Anggota Dewan), Pejabat bekerja untuk perusahaan setiap hari, dan mereka menggunakan uang mereka sendiri saat bertransaksi . (Pemegang Saham 10% dan Anggota Dewan seringkali adalah manajer dana yang mengelola uang orang lain.) Dengan demikian, transaksi orang dalam yang dilakukan oleh Pejabat jauh lebih signifikan dan harus ditangani dengan tepat.
Seperti Skor Sentimen Internal, Skor Sentimen Pejabat adalah hasil dari model kuantitatif multi-faktor yang canggih yang mengidentifikasi perusahaan dengan tingkat akumulasi pejabat tertinggi.
Frekuensi Pembaruan: Setiap Hari
Metrik Utama Orang Dalam
Kartu ini menunjukkan peringkat perusahaan berdasarkan berbagai metrik internal. Peringkat persentil menunjukkan bagaimana perusahaan ini dibandingkan dengan perusahaan lain di pasar AS. Peringkat yang lebih tinggi menunjukkan situasi yang lebih baik.
Sebagai contoh, secara umum diterima bahwa pembelian oleh orang dalam perusahaan adalah indikator positif, sehingga perusahaan dengan lebih banyak pembelian oleh orang dalam akan mendapat peringkat lebih tinggi daripada perusahaan dengan lebih sedikit pembelian oleh orang dalam (atau bahkan penjualan oleh orang dalam).
Jumlah Bersih Pembelian oleh Orang Dalam (Peringkat)
0 ( )
5106 out of 11323Jumlah Bersih Pembelian oleh Orang Dalam adalah total jumlah orang dalam yang membeli dikurangi total jumlah orang dalam yang menjual dalam 90 hari terakhir. Peringkat persentil ditunjukkan di sini (kisaran dari 0 hingga 100%).
Persentase Saham yang Dibeli oleh Orang Dalam (Peringkat)
0.000 %( )
5079 out of 11244Persentase Saham yang Dibeli oleh Orang Dalam adalah total jumlah saham yang dibeli oleh orang dalam dikurangi total jumlah saham yang dijual oleh orang dalam dalam 90 hari terakhir, dibagi dengan total jumlah saham yang beredar dan dikalikan dengan 100.
Grafik Perdagangan Orang Dalam
Grafik berikut menunjukkan Sensei Biotherapeutics, Inc. transaksi orang dalam. Orang dalam adalah pejabat, direktur, atau investor signifikan dalam suatu perusahaan. Secara umum, melakukan transaksi di perusahaan mereka berdasarkan informasi material yang belum dipublikasikan adalah ilegal bagi orang dalam. Ini tidak berarti bahwa mereka dilarang melakukan transaksi apa pun di perusahaan mereka sendiri. Namun, mereka wajib melaporkan semua transaksi kepada SEC melalui Formulir 4.
Daftar Orang Dalam dan Metrik Profitabilitas
Tabel ini menampilkan daftar orang dalam yang diketahui, dan dibuat secara otomatis dari pengajuan yang diungkapkan kepada SEC. Selain nama, jabatan terbaru, dan sebutan direktur, pejabat, atau pemilik 10%, kami memberikan kepemilikan terbaru yang diungkapkan. Selain itu, jika memungkinkan, kami memberikan kinerja perdagangan historis untuk orang dalam tersebut. Kinerja perdagangan historis adalah rata-rata tertimbang dari kinerja transaksi pembelian pasar terbuka aktual yang dilakukan oleh orang dalam tersebut. Untuk informasi lebih lanjut tentang bagaimana ini dihitung, tonton webinar YouTube ini.
See our leaderboard of most profitable insider traders.
| Orang Dalam | Rata-rata Keuntungan (%) | Saham Dimiliki |
Terbagi Disesuaikan |
|---|---|---|---|
|
Apeiron Investment Group Ltd.
10% Owner -
|
0 | 0 | |
| Samuel Broder Director - [D] | 8,932 | 447 | |
|
Cambrian BioPharma Inc
10% Owner -
|
3,653,120 | 182,656 | |
| John Celebi PRESIDENT AND CEO, Director - [D] [O] | 105,862 | 5,293 | |
| Erin Colgan CHIEF FINANCIAL OFFICER - [O] | 67,462 | 3,373 | |
| Jessie English Director - [D] | 8,932 | 447 |
| Orang Dalam | Rata-rata Keuntungan (%) | Saham Dimiliki |
Terbagi Disesuaikan |
|---|---|---|---|
| Patrick Stephen Gallagher Chief Business Officer - [O] | 34,130 | 1,706 | |
|
H&s Investments I Lp
10% Owner -
|
4,425,998 | 221,300 | |
|
H&s Ventures Llc
10% Owner -
|
4,425,998 | 221,300 | |
| Bob Holmen Director - [D] | 25,598 | 1,280 | |
| Kristian Humer Director - [D] | 8,932 | 447 | |
|
James Peyer
Director, 10% Owner -
[D]
|
3,653,120 | 182,656 | |
| Robert Hamilton Pierce Chief R&D Officer - [O] | 21,000 | 1,050 |
| Orang Dalam | Rata-rata Keuntungan (%) | Saham Dimiliki |
Terbagi Disesuaikan |
|---|---|---|---|
| Thomas G Ricks Director - [D] | 343,863 | 17,193 | |
| William R Ringo Director - [D] | 23,399 | 1,170 | |
|
Henry Samueli
10% Owner -
|
4,425,998 | 221,300 | |
|
Susan Samueli
10% Owner -
|
4,425,998 | 221,300 | |
|
Michael Schulman
10% Owner -
|
4,425,998 | 221,300 | |
| Deneen Vojta Director - [D] | 8,932 | 447 | |
| der Horst Edward van CHIEF SCIENTIFIC OFFICER - [O] | 59,794 | 2,990 |
Report errors via our new Insider Auditing Tool
Rekam Jejak Pembelian Orang Dalam - Analisis Keuntungan Jangka Pendek
Pada bagian ini, kami menganalisis profitabilitas setiap pembelian saham oleh orang dalam di pasar terbuka yang tidak direncanakan yang dilakukan di SNSE / Sensei Biotherapeutics, Inc.. Analisis ini membantu memahami apakah orang dalam tersebut secara konsisten menghasilkan pengembalian abnormal, dan layak untuk diikuti. Analisis ini dilakukan selama satu tahun setelah setiap transaksi, dan hasilnya bersifat teoretis .
Tabel berikut menunjukkan pembelian pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Ang Adjusted Shares ay ang jumlah saham yang disesuaikan dengan pemisahan saham (stock split).
Rekam Jejak Penjualan Orang Dalam - Analisis Kerugian Jangka Pendek
Dalam bagian ini, kami menganalisis penghindaran kerugian jangka pendek dari setiap penjualan dalam pasar terbuka yang tidak direncanakan oleh orang dalam yang dilakukan di SNSE / Sensei Biotherapeutics, Inc.. Pola penghindaran kerugian yang konsisten dapat menunjukkan bahwa transaksi penjualan di masa mendatang dapat memprediksi penurunan harga. Analisis ini berlaku untuk satu tahun setelah setiap perdagangan, dan hasilnya bersifat teoretis .
Tabel berikut menunjukkan penjualan pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Ang Adjusted Shares ay ang jumlah saham yang disesuaikan dengan pemisahan saham (stock split).
Riwayat Transaksi
Klik ikon tautan untuk melihat riwayat transaksi lengkap. Transaksi yang dilaporkan sebagai bagian dari rencana perdagangan otomatis 10b5-1 akan memiliki tanda X di kolom yang bertanda 10b-5.
| Berkas Tanggal |
Perdagangan Tanggal |
Formulir | Orang Dalam | Ticker | Judul Keamanan | Kode | Langsung | Latihan Harga |
Satuan Harga |
Unit Diubah |
Nilai Diubah (1 ribu) |
Sisa Pilihan |
Sisa Saham |
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-02-26 | 2025-02-19 | 4 | Celebi John | SNSE | Common Stock | D | 0.4760 | -5,558 | -3 | 105,862 | ||||
| 2025-02-26 | 2025-02-19 | 4 | van der Horst Edward | SNSE | Common Stock | D | 0.4760 | -2,276 | -1 | 59,794 | ||||
| 2024-02-16 | 2024-02-15 | 4 | van der Horst Edward | SNSE | Common Stock | D | 0.7900 | -2,843 | -2 | 56,070 | ||||
| 2024-02-16 | 2024-02-15 | 4 | Celebi John | SNSE | Common Stock | D | 0.7900 | -5,891 | -5 | 105,420 | ||||
| 2024-02-16 | 2024-02-15 | 4 | Colgan Erin | SNSE | Common Stock | D | 0.7900 | -3,627 | -3 | 67,462 | ||||
| 2023-09-13 | 2023-09-11 | 4 | Celebi John | SNSE | Common Stock | D | 0.8500 | 500 | 0 | 111,311 | ||||
| 2023-09-11 | 2023-02-15 | 4 | Gallagher Patrick Stephen | SNSE | Common Stock | D | 1.5000 | -9,383 | -14 | 34,130 | ||||
| 2023-09-11 | 2023-02-15 | 4 | Celebi John | SNSE | Common Stock | D | 1.5000 | -20,492 | -31 | 110,811 | ||||
| 2023-09-11 | 2023-02-15 | 4 | van der Horst Edward | SNSE | Common Stock | D | 1.5000 | -9,525 | -14 | 52,913 | ||||
| 2023-09-11 | 2023-02-15 | 4 | Colgan Erin | SNSE | Common Stock | D | 1.5000 | -10,943 | -16 | 68,089 | ||||
| 2023-08-02 | 2023-07-31 | 4 | Peyer James | SNSE | Common Stock | I | 1.2600 | -1,587,302 | -2,000 | 3,653,120 | ||||
| 2023-08-02 | 2023-07-31 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 1.2600 | -1,587,302 | -2,000 | 3,653,120 | ||||
| 2023-07-12 | 2023-07-10 | 4 | RINGO WILLIAM R | SNSE | Common Stock | D | 4,466 | 23,399 | ||||||
| 2023-07-12 | 2023-07-10 | 4 | RICKS THOMAS G | SNSE | Common Stock | D | 4,466 | 8,932 | ||||||
| 2023-07-12 | 2023-07-10 | 4 | Broder Samuel | SNSE | Common Stock | D | 4,466 | 8,932 | ||||||
| 2023-07-12 | 2023-07-10 | 4 | Humer Kristian | SNSE | Common Stock | D | 4,466 | 8,932 | ||||||
| 2023-07-12 | 2023-07-10 | 4 | English Jessie | SNSE | Common Stock | D | 4,466 | 8,932 | ||||||
| 2023-07-12 | 2023-07-10 | 4 | Holmen Bob | SNSE | Common Stock | D | 4,466 | 25,598 | ||||||
| 2023-07-12 | 2023-07-10 | 4 | Vojta Deneen | SNSE | Common Stock | D | 4,466 | 8,932 | ||||||
| 2023-07-12 | 2023-07-10 | 4 | Peyer James | SNSE | Common Stock | I | 4,466 | 5,240,422 | ||||||
| 2023-07-12 | 2023-07-10 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 4,466 | 5,240,422 | ||||||
| 2023-06-02 | 2023-06-01 | 4 | Apeiron Investment Group Ltd. By Presight Sensei Co-Invest Fund, L.P. | SNSE | Common Stock | I | 1.5800 | -955,738 | -1,510 | 0 | ||||
| 2023-06-02 | 2023-06-01 | 4 | Apeiron Investment Group Ltd. By Apeiron Investment Group Ltd. | SNSE | Common Stock | I | 1.5800 | -2,485,923 | -3,928 | 0 | ||||
| 2023-03-29 | 2023-02-15 | 4/A | Gallagher Patrick Stephen | SNSE | Common Stock | D | 14,200 | 43,513 | ||||||
| 2023-03-29 | 2023-02-15 | 4/A | Gallagher Patrick Stephen | SNSE | Common Stock | D | 29,313 | 29,313 | ||||||
| 2023-03-29 | 2023-02-15 | 4/A | Celebi John | SNSE | Common Stock | D | 21,300 | 131,303 | ||||||
| 2023-03-29 | 2023-02-15 | 4/A | Celebi John | SNSE | Common Stock | D | 51,893 | 110,003 | ||||||
| 2023-03-29 | 2023-02-15 | 4/A | Colgan Erin | SNSE | Common Stock | D | 21,300 | 79,032 | ||||||
| 2023-03-29 | 2023-02-15 | 4/A | Colgan Erin | SNSE | Common Stock | D | 30,046 | 57,732 | ||||||
| 2023-03-07 | 2022-06-10 | 4/A | Cambrian BioPharma Inc | SNSE | Restricted Stock Unit Grant | D | 4,466 | 5,235,956 | ||||||
| 2023-02-27 | 2023-02-23 | 4 | Apeiron Investment Group Ltd. By Apeiron Investment Group Ltd. | SNSE | Common Stock | I | 1.6023 | 1,100 | 2 | 2,485,923 | ||||
| 2023-02-27 | 2023-02-23 | 4 | Apeiron Investment Group Ltd. By Apeiron Investment Group Ltd. | SNSE | Common Stock | I | 1.6150 | 1,100 | 2 | 2,484,823 | ||||
| 2023-02-17 | 2023-02-15 | 4 | Celebi John | SNSE | Common Stock | D | 21,300 | 127,307 | ||||||
| 2023-02-17 | 2023-02-15 | 4 | Celebi John | SNSE | Common Stock | D | 51,893 | 106,007 | ||||||
| 2023-02-17 | 2023-02-15 | 4 | Gallagher Patrick Stephen | SNSE | Common Stock | D | 14,200 | 43,515 | ||||||
| 2023-02-17 | 2023-02-15 | 4 | Gallagher Patrick Stephen | SNSE | Common Stock | D | 29,313 | 29,313 | ||||||
| 2023-02-17 | 2023-02-15 | 4 | Colgan Erin | SNSE | Common Stock | D | 21,300 | 73,032 | ||||||
| 2023-02-17 | 2023-02-15 | 4 | Colgan Erin | SNSE | Common Stock | D | 30,046 | 51,732 | ||||||
| 2023-02-17 | 2023-02-15 | 4 | van der Horst Edward | SNSE | Common Stock | D | 17,700 | 62,438 | ||||||
| 2023-02-17 | 2023-02-15 | 4 | van der Horst Edward | SNSE | Common Stock | D | 23,565 | 44,738 | ||||||
| 2022-12-16 | 3 | van der Horst Edward | SNSE | Common Stock | D | 21,173 | ||||||||
| 2022-08-01 | 2022-06-10 | 4/A | Peyer James | SNSE | Restricted Stock Unit Grant | I | 4,466 | 5,235,956 | ||||||
| 2022-08-01 | 3/A | Peyer James | SNSE | Common Stock | I | 2,282,827 | ||||||||
| 2022-07-20 | 3 | Presight Co-Invest Management, L.L.C. By Apeiron Investment Group Ltd. | SNSE | Common Stock | I | 2,483,723 | ||||||||
| 2022-07-20 | 3 | Presight Co-Invest Management, L.L.C. By Presight Sensei Co-Invest Fund, L.P. | SNSE | Common Stock | I | 955,738 | ||||||||
| 2022-06-14 | 2022-06-10 | 4 | Cambrian BioPharma Inc | SNSE | Restricted Stock Unit Grant | D | 4,466 | 5,235,954 | ||||||
| 2022-06-14 | 2022-06-10 | 4 | Peyer James | SNSE | Restricted Stock Unit Grant | I | 4,466 | 5,235,954 | ||||||
| 2022-06-14 | 2022-06-10 | 4 | Humer Kristian | SNSE | Common Stock | D | 4,466 | 4,466 | ||||||
| 2022-06-14 | 2022-06-10 | 4 | Vojta Deneen | SNSE | Common Stock | D | 4,466 | 4,466 | ||||||
| 2022-06-14 | 2022-06-10 | 4 | RICKS THOMAS G | SNSE | Common Stock | D | 4,466 | 4,466 | ||||||
| 2022-06-14 | 2022-06-10 | 4 | English Jessie | SNSE | Common Stock | D | 4,466 | 4,466 | ||||||
| 2022-06-14 | 2022-06-10 | 4 | Holmen Bob | SNSE | Common Stock | D | 4,466 | 21,132 | ||||||
| 2022-06-14 | 2022-06-10 | 4 | Broder Samuel | SNSE | Common Stock | D | 4,466 | 4,466 | ||||||
| 2022-06-10 | 2022-03-02 | 4/A | Cambrian BioPharma Inc | SNSE | Common Stock | D | 3.2000 | 1,203 | 4 | 5,231,488 | ||||
| 2022-06-10 | 2022-03-02 | 4/A | Peyer James | SNSE | Common Stock | I | 3.2000 | 1,203 | 4 | 5,231,488 | ||||
| 2022-04-21 | 2021-03-23 | 4/A | Peyer James | SNSE | Common Stock | I | 14.3400 | 9,500 | 136 | 4,798,293 | ||||
| 2022-04-21 | 2021-02-18 | 4/A | Peyer James | SNSE | Common Stock | I | 19.7500 | 752 | 15 | 4,690,905 | ||||
| 2022-04-21 | 2021-03-23 | 4/A | Cambrian BioPharma Inc | SNSE | Common Stock | D | 14.3400 | 9,500 | 136 | 4,798,293 | ||||
| 2022-04-21 | 2021-02-18 | 4/A | Cambrian BioPharma Inc | SNSE | Common Stock | D | 19.7500 | 752 | 15 | 4,690,905 | ||||
| 2022-03-09 | 2022-03-08 | 4 | RINGO WILLIAM R | SNSE | Stock Option (Right to Buy) | D | 3.08 | 29,100 | 29,100 | |||||
| 2022-03-09 | 2022-03-08 | 4 | RINGO WILLIAM R | SNSE | Common Stock | D | 10,000 | 18,933 | ||||||
| 2022-03-09 | 2022-03-08 | 4 | RINGO WILLIAM R | SNSE | Common Stock | D | 8,933 | 8,933 | ||||||
| 2022-03-02 | 2022-03-02 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 3.2000 | 1,203 | 4 | 5,231,989 | ||||
| 2022-03-02 | 2022-03-02 | 4 | Peyer James | SNSE | Common Stock | I | 3.2000 | 1,203 | 4 | 5,231,989 | ||||
| 2022-03-01 | 2022-03-01 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 3.6000 | 2,458 | 9 | 5,230,786 | ||||
| 2022-03-01 | 2022-02-28 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 3.6000 | 42 | 0 | 5,228,328 | ||||
| 2022-03-01 | 2022-03-01 | 4 | Peyer James | SNSE | Common Stock | I | 3.6000 | 2,458 | 9 | 5,230,786 | ||||
| 2022-03-01 | 2022-02-28 | 4 | Peyer James | SNSE | Common Stock | I | 3.6000 | 42 | 0 | 5,228,328 | ||||
| 2022-02-28 | 2022-02-25 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 3.6500 | 2,500 | 9 | 5,228,286 | ||||
| 2022-02-28 | 2022-02-25 | 4 | Peyer James | SNSE | Common Stock | I | 3.6500 | 2,500 | 9 | 5,228,286 | ||||
| 2022-02-24 | 2022-02-24 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 3.6300 | 15,000 | 54 | 5,225,786 | ||||
| 2022-02-24 | 2022-02-23 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 3.8000 | 2,500 | 10 | 5,210,786 | ||||
| 2022-02-24 | 2022-02-24 | 4 | Peyer James | SNSE | Common Stock | I | 3.6300 | 15,000 | 54 | 5,225,786 | ||||
| 2022-02-24 | 2022-02-23 | 4 | Peyer James | SNSE | Common Stock | I | 3.8000 | 2,500 | 10 | 5,210,786 | ||||
| 2022-02-22 | 2022-02-18 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 3.9700 | 15,000 | 60 | 5,208,286 | ||||
| 2022-02-22 | 2022-02-17 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 4.1700 | 4,949 | 21 | 5,193,286 | ||||
| 2022-02-22 | 2022-02-18 | 4 | Peyer James | SNSE | Common Stock | I | 3.9700 | 15,000 | 60 | 5,208,286 | ||||
| 2022-02-22 | 2022-02-17 | 4 | Peyer James | SNSE | Common Stock | I | 4.1700 | 4,949 | 21 | 5,193,286 | ||||
| 2022-02-17 | 2022-02-15 | 4 | Pierce Robert Hamilton | SNSE | Stock Option (Right to Buy) | D | 4.30 | 62,000 | 62,000 | |||||
| 2022-02-17 | 2022-02-15 | 4 | Pierce Robert Hamilton | SNSE | Common Stock | D | 21,000 | 21,000 | ||||||
| 2022-02-17 | 2022-02-15 | 4 | Colgan Erin | SNSE | Stock Option (Right to Buy) | D | 4.30 | 62,000 | 62,000 | |||||
| 2022-02-17 | 2022-02-15 | 4 | Colgan Erin | SNSE | Common Stock | D | 21,000 | 21,686 | ||||||
| 2022-02-17 | 2022-02-15 | 4 | Celebi John | SNSE | Stock Option (Right to Buy) | D | 4.30 | 161,600 | 161,600 | |||||
| 2022-02-17 | 2022-02-15 | 4 | Celebi John | SNSE | Common Stock | D | 53,900 | 54,114 | ||||||
| 2022-02-16 | 2022-02-16 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 4.2500 | 2,551 | 11 | 5,188,337 | ||||
| 2022-02-16 | 2022-02-14 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 4.1800 | 10,000 | 42 | 5,185,786 | ||||
| 2022-02-16 | 2022-02-16 | 4 | Peyer James | SNSE | Common Stock | D | 4.2500 | 2,551 | 11 | 5,188,337 | ||||
| 2022-02-16 | 2022-02-14 | 4 | Peyer James | SNSE | Common Stock | I | 4.1800 | 10,000 | 42 | 5,185,786 | ||||
| 2022-02-14 | 2022-02-11 | 4 | Peyer James | SNSE | Common Stock | I | 4.4000 | 12,500 | 55 | 5,175,786 | ||||
| 2022-02-14 | 2022-02-10 | 4 | Peyer James | SNSE | Common Stock | I | 4.5800 | 5,000 | 23 | 5,163,286 | ||||
| 2022-02-14 | 2022-02-11 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 4.4000 | 12,500 | 55 | 5,175,786 | ||||
| 2022-02-14 | 2022-02-10 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 4.5800 | 5,000 | 23 | 5,163,286 | ||||
| 2022-02-08 | 2022-02-08 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 4.3300 | 10,000 | 43 | 5,158,286 | ||||
| 2022-02-08 | 2022-02-04 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 4.4500 | 2,500 | 11 | 5,148,286 | ||||
| 2022-02-08 | 2022-02-03 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 4.6500 | 17,500 | 81 | 5,145,786 | ||||
| 2022-02-08 | 2022-02-08 | 4 | Peyer James | SNSE | Common Stock | I | 4.3300 | 10,000 | 43 | 5,158,286 | ||||
| 2022-02-08 | 2022-02-04 | 4 | Peyer James | SNSE | Common Stock | I | 4.4500 | 2,500 | 11 | 5,148,286 | ||||
| 2022-02-08 | 2022-02-03 | 4 | Peyer James | SNSE | Common Stock | I | 4.6500 | 17,500 | 81 | 5,145,786 | ||||
| 2022-01-31 | 2022-01-28 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 4.2200 | 8,900 | 38 | 5,128,286 | ||||
| 2022-01-31 | 2022-01-27 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 4.3100 | 6,100 | 26 | 5,119,386 | ||||
| 2022-01-31 | 2022-01-28 | 4 | Peyer James | SNSE | Common Stock | I | 4.2200 | 8,900 | 38 | 5,128,286 | ||||
| 2022-01-31 | 2022-01-27 | 4 | Peyer James | SNSE | Common Stock | I | 4.3100 | 6,100 | 26 | 5,119,386 | ||||
| 2022-01-27 | 2022-01-26 | 4 | Peyer James | SNSE | Common Stock | I | 4.6200 | 29,900 | 138 | 5,113,286 | ||||
| 2022-01-27 | 2022-01-25 | 4 | Peyer James | SNSE | Common Stock | I | 4.8600 | 20,100 | 98 | 5,083,386 | ||||
| 2022-01-27 | 2022-01-26 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 4.6200 | 29,900 | 138 | 5,113,286 | ||||
| 2022-01-27 | 2022-01-25 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 4.8600 | 20,100 | 98 | 5,083,386 | ||||
| 2022-01-25 | 2022-01-24 | 4 | Peyer James | SNSE | Common Stock | I | 4.6900 | 22,707 | 106 | 5,063,286 | ||||
| 2022-01-25 | 2022-01-21 | 4 | Peyer James | SNSE | Common Stock | I | 4.9400 | 24,703 | 122 | 5,040,579 | ||||
| 2022-01-25 | 2022-01-24 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 4.6900 | 22,707 | 106 | 5,063,286 | ||||
| 2022-01-25 | 2022-01-21 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 4.9400 | 24,703 | 122 | 5,040,579 | ||||
| 2022-01-21 | 2022-01-20 | 4 | Peyer James | SNSE | Common Stock | I | 5.1700 | 20,000 | 103 | 5,015,876 | ||||
| 2022-01-21 | 2022-01-19 | 4 | Peyer James | SNSE | Common Stock | I | 4.9700 | 10,244 | 51 | 4,995,876 | ||||
| 2022-01-21 | 2022-01-20 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 5.1700 | 20,000 | 103 | 5,015,876 | ||||
| 2022-01-21 | 2022-01-19 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 4.9700 | 10,244 | 51 | 4,995,876 | ||||
| 2022-01-20 | 2022-01-18 | 4 | Peyer James | SNSE | Common Stock | I | 5.0800 | 10,000 | 51 | 4,985,632 | ||||
| 2022-01-20 | 2022-01-18 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 5.0800 | 10,000 | 51 | 4,985,632 | ||||
| 2022-01-18 | 2022-01-14 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 4.9900 | 6,219 | 31 | 4,975,632 | ||||
| 2022-01-18 | 2022-01-13 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 5.1300 | 19,953 | 102 | 4,969,413 | ||||
| 2022-01-18 | 2022-01-14 | 4 | Peyer James | SNSE | Common Stock | I | 4.9900 | 6,219 | 31 | 4,975,632 | ||||
| 2022-01-18 | 2022-01-13 | 4 | Peyer James | SNSE | Common Stock | I | 5.1300 | 19,953 | 102 | 4,969,413 | ||||
| 2022-01-13 | 2022-01-12 | 4 | Peyer James | SNSE | Common Stock | I | 5.2200 | 9,202 | 48 | 4,949,460 | ||||
| 2022-01-13 | 2022-01-11 | 4 | Peyer James | SNSE | Common Stock | I | 5.1800 | 10,845 | 56 | 4,940,258 | ||||
| 2022-01-13 | 2022-01-12 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 5.2200 | 9,202 | 48 | 4,949,460 | ||||
| 2022-01-13 | 2022-01-11 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 5.1800 | 10,845 | 56 | 4,940,258 | ||||
| 2022-01-11 | 2022-01-10 | 4 | Peyer James | SNSE | Common Stock | I | 5.2800 | 10,000 | 53 | 4,929,413 | ||||
| 2022-01-11 | 2022-01-10 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 5.2800 | 10,000 | 53 | 4,929,413 | ||||
| 2022-01-03 | 2021-12-30 | 4 | Peyer James | SNSE | Common Stock | I | 4.8500 | 1,127 | 5 | 4,919,413 | ||||
| 2022-01-03 | 2021-12-30 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 4.8500 | 1,127 | 5 | 4,919,413 | ||||
| 2021-12-30 | 2021-12-29 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 4.9800 | 69,000 | 344 | 4,918,286 | ||||
| 2021-12-30 | 2021-12-29 | 4 | Peyer James | SNSE | Common Stock | I | 4.9800 | 69,000 | 344 | 4,918,286 | ||||
| 2021-12-29 | 2021-12-28 | 4 | Peyer James | SNSE | Common Stock | I | 5.2800 | 11,288 | 60 | 4,849,286 | ||||
| 2021-12-29 | 2021-12-28 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 5.2800 | 11,288 | 60 | 4,849,286 | ||||
| 2021-12-27 | 2021-12-27 | 4 | Peyer James | SNSE | Common Stock | I | 5.3000 | 3,712 | 20 | 4,837,998 | ||||
| 2021-12-27 | 2021-12-27 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 5.3000 | 3,712 | 20 | 4,837,998 | ||||
| 2021-12-23 | 2021-12-23 | 4 | Peyer James | SNSE | Common Stock | I | 5.2700 | 11,000 | 58 | 4,834,286 | ||||
| 2021-12-23 | 2021-12-23 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 5.2700 | 11,000 | 58 | 4,834,286 | ||||
| 2021-12-21 | 2021-12-17 | 4 | Peyer James | SNSE | Common Stock | I | 5.2900 | 117 | 1 | 4,823,286 | ||||
| 2021-12-21 | 2021-12-17 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 5.2900 | 117 | 1 | 4,823,286 | ||||
| 2021-12-20 | 2021-12-16 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 5.2500 | 10,925 | 57 | 4,823,169 | ||||
| 2021-12-20 | 2021-12-16 | 4 | Peyer James | SNSE | Common Stock | I | 5.2500 | 10,925 | 57 | 4,823,169 | ||||
| 2021-12-13 | 2021-12-10 | 4 | RICKS THOMAS G | SNSE | Common Stock | I | 5.8600 | 20,000 | 117 | 341,769 | ||||
| 2021-12-13 | 2021-12-09 | 4 | RICKS THOMAS G | SNSE | Common Stock | I | 6.6200 | 20,000 | 132 | 321,769 | ||||
| 2021-08-12 | 2021-08-11 | 4 | Pierce Robert Hamilton By spouse | SNSE | Common Stock | I | 7.3436 | -16,030 | -118 | 0 | ||||
| 2021-08-10 | 2021-08-10 | 4 | Pierce Robert Hamilton By spouse | SNSE | Common Stock | I | 7.1289 | -66,350 | -473 | 16,030 | ||||
| 2021-08-10 | 2021-08-09 | 4 | Pierce Robert Hamilton By spouse | SNSE | Common Stock | I | 7.0603 | -6,982 | -49 | 82,380 | ||||
| 2021-08-10 | 2021-08-06 | 4 | Pierce Robert Hamilton By spouse | SNSE | Common Stock | I | 7.1127 | -6,460 | -46 | 89,362 | ||||
| 2021-08-10 | 3/A | Pierce Robert Hamilton By spouse | SNSE | Common Stock | I | 95,822 | ||||||||
| 2021-08-02 | 2021-07-30 | 4 | Humer Kristian | SNSE | Stock Option (Right to Buy) | D | 7.89 | 16,667 | 16,667 | |||||
| 2021-05-06 | 2021-05-05 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 12.0000 | 350 | 4 | 4,812,244 | ||||
| 2021-05-06 | 2021-05-05 | 4 | Peyer James | SNSE | Common Stock | I | 12.0000 | 350 | 4 | 4,812,244 | ||||
| 2021-04-21 | 2021-04-20 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 12.7700 | 385 | 5 | 4,811,894 | ||||
| 2021-04-21 | 2021-04-20 | 4 | Peyer James | SNSE | Common Stock | I | 12.7700 | 385 | 5 | 4,811,894 | ||||
| 2021-04-20 | 2021-04-19 | 4 | Peyer James | SNSE | Common Stock | I | 13.3800 | 1,965 | 26 | 4,811,509 | ||||
| 2021-04-20 | 2021-04-19 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 13.3800 | 1,965 | 26 | 4,811,509 | ||||
| 2021-04-14 | 2021-04-13 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 14.0000 | 2,000 | 28 | 4,809,544 | ||||
| 2021-04-14 | 2021-04-13 | 4 | Peyer James | SNSE | Common Stock | I | 14.0000 | 2,000 | 28 | 4,809,544 | ||||
| 2021-04-08 | 2021-04-07 | 4 | Peyer James | SNSE | Common Stock | I | 14.0000 | 2,000 | 28 | 4,807,544 | ||||
| 2021-04-08 | 2021-04-07 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 14.0000 | 2,000 | 28 | 4,807,544 | ||||
| 2021-04-05 | 2021-04-01 | 4 | English Jessie | SNSE | Stock Option (Right to Buy) | D | 14.42 | 16,667 | 16,667 | |||||
| 2021-04-02 | 2021-04-01 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 14.0000 | 1,000 | 14 | 4,805,544 | ||||
| 2021-04-02 | 2021-04-01 | 4 | Peyer James | SNSE | Common Stock | I | 14.0000 | 1,000 | 14 | 4,805,544 | ||||
| 2021-03-31 | 2021-03-30 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 12.0000 | 2,000 | 24 | 4,804,544 | ||||
| 2021-03-31 | 2021-03-30 | 4 | Peyer James | SNSE | Common Stock | I | 12.0000 | 2,000 | 24 | 4,804,544 | ||||
| 2021-03-25 | 2021-03-24 | 4 | Peyer James | SNSE | Common Stock | I | 14.1200 | 3,750 | 53 | 4,802,544 | ||||
| 2021-03-25 | 2021-03-24 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 14.1200 | 3,750 | 53 | 4,802,544 | ||||
| 2021-03-24 | 2021-03-23 | 4 | Peyer James | SNSE | Common Stock | I | 14.3400 | 10,000 | 143 | 4,798,794 | ||||
| 2021-03-24 | 2021-03-23 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 14.3400 | 10,000 | 143 | 4,798,794 | ||||
| 2021-03-23 | 2021-03-22 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 15.0200 | 2,183 | 33 | 4,788,794 | ||||
| 2021-03-23 | 2021-03-22 | 4 | Peyer James | SNSE | Common Stock | I | 15.0200 | 2,183 | 33 | 4,788,794 | ||||
| 2021-03-19 | 2021-03-18 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 15.2500 | 817 | 12 | 4,786,611 | ||||
| 2021-03-19 | 2021-03-18 | 4 | Peyer James | SNSE | Common Stock | I | 15.2500 | 817 | 12 | 4,786,611 | ||||
| 2021-03-10 | 2021-03-08 | 4 | Peyer James | SNSE | Common Stock | I | 15.2490 | 1,000 | 15 | 4,785,794 | ||||
| 2021-03-10 | 2021-03-08 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 15.2490 | 1,000 | 15 | 4,785,794 | ||||
| 2021-03-08 | 2021-03-05 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 13.7500 | 8,000 | 110 | 4,784,794 | ||||
| 2021-03-08 | 2021-03-05 | 4 | Peyer James | SNSE | Common Stock | I | 13.7500 | 8,000 | 110 | 4,784,794 | ||||
| 2021-03-05 | 2021-03-04 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 14.1250 | 2,000 | 28 | 4,776,794 | ||||
| 2021-03-05 | 2021-03-03 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 15.8500 | 3,000 | 48 | 4,774,794 | ||||
| 2021-03-05 | 2021-03-04 | 4 | Peyer James | SNSE | Common Stock | I | 14.1250 | 2,000 | 28 | 4,776,794 | ||||
| 2021-03-05 | 2021-03-03 | 4 | Peyer James | SNSE | Common Stock | I | 15.8500 | 3,000 | 48 | 4,774,794 | ||||
| 2021-03-03 | 2021-03-02 | 4 | Peyer James | SNSE | Common Stock | I | 16.2500 | 3,000 | 49 | 4,771,794 | ||||
| 2021-03-03 | 2021-03-02 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 16.2500 | 3,000 | 49 | 4,771,794 | ||||
| 2021-03-02 | 2021-02-26 | 4 | Peyer James | SNSE | Common Stock | I | 16.2500 | 5,000 | 81 | 4,768,794 | ||||
| 2021-03-02 | 2021-02-26 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 16.2500 | 5,000 | 81 | 4,768,794 | ||||
| 2021-02-26 | 2021-02-25 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 15.7900 | 12,000 | 189 | 4,763,794 | ||||
| 2021-02-26 | 2021-02-24 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 18.4200 | 900 | 17 | 4,751,794 | ||||
| 2021-02-26 | 2021-02-24 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 16.8400 | 18,100 | 305 | 4,750,894 | ||||
| 2021-02-26 | 2021-02-25 | 4 | Peyer James | SNSE | Common Stock | I | 15.7900 | 12,000 | 189 | 4,763,794 | ||||
| 2021-02-26 | 2021-02-24 | 4 | Peyer James | SNSE | Common Stock | I | 18.4200 | 900 | 17 | 4,751,794 | ||||
| 2021-02-26 | 2021-02-24 | 4 | Peyer James | SNSE | Common Stock | I | 16.8400 | 18,100 | 305 | 4,750,894 | ||||
| 2021-02-25 | 2021-02-23 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 18.1000 | 14,300 | 259 | 4,732,794 | ||||
| 2021-02-25 | 2021-02-23 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 17.0400 | 6,000 | 102 | 4,718,494 | ||||
| 2021-02-25 | 2021-02-23 | 4 | Peyer James | SNSE | Common Stock | I | 18.1000 | 14,300 | 259 | 4,732,794 | ||||
| 2021-02-25 | 2021-02-23 | 4 | Peyer James | SNSE | Common Stock | I | 17.0400 | 6,000 | 102 | 4,718,494 | ||||
| 2021-02-24 | 2021-02-22 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 18.8800 | 9,802 | 185 | 4,712,494 | ||||
| 2021-02-24 | 2021-02-22 | 4 | Peyer James | SNSE | Common Stock | I | 18.8800 | 9,802 | 185 | 4,712,494 | ||||
| 2021-02-23 | 2021-02-19 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 19.7700 | 11,786 | 233 | 4,702,692 | ||||
| 2021-02-23 | 2021-02-19 | 4 | Peyer James | SNSE | Common Stock | I | 19.7700 | 11,786 | 233 | 4,702,692 | ||||
| 2021-02-19 | 2021-02-18 | 4 | Peyer James | SNSE | Common Stock | I | 19.7500 | 753 | 15 | 4,690,906 | ||||
| 2021-02-19 | 2021-02-18 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 19.7500 | 753 | 15 | 4,690,906 | ||||
| 2021-02-10 | 2021-02-08 | 4 | RICKS THOMAS G | SNSE | Series BB Preferred Convertible Stock | I | -3,037,849 | 0 | ||||||
| 2021-02-10 | 2021-02-08 | 4 | RICKS THOMAS G | SNSE | Series AA Preferred Convertible Stock | I | -11,447,156 | 0 | ||||||
| 2021-02-10 | 2021-02-08 | 4 | RICKS THOMAS G | SNSE | Common Stock | I | 301,769 | 301,769 | ||||||
| 2021-02-10 | 2021-02-08 | 4 | Peyer James See footnotes | SNSE | Series BB Preferred Convertible Stock | I | -4,821,996 | 0 | ||||||
| 2021-02-10 | 2021-02-08 | 4 | Peyer James | SNSE | Series AA Preferred Convertible Stock | I | -110,729,827 | 0 | ||||||
| 2021-02-10 | 2021-02-08 | 4 | Peyer James | SNSE | Common Stock | I | 2,407,328 | 4,690,153 | ||||||
| 2021-02-10 | 2021-02-08 | 4 | H&S INVESTMENTS I LP | SNSE | Series AA Convertible Preferred Stock | D | -209,368,245 | 0 | ||||||
| 2021-02-10 | 2021-02-08 | 4 | H&S INVESTMENTS I LP | SNSE | Common Stock | D | 4,361,835 | 4,425,998 | ||||||
| 2021-02-10 | 2021-02-08 | 4 | Cambrian BioPharma Inc | SNSE | Series BB Preferred Convertible Stock | D | -4,821,996 | 0 | ||||||
| 2021-02-10 | 2021-02-08 | 4 | Cambrian BioPharma Inc | SNSE | Series AA Preferred Convertible Stock | D | -110,729,827 | 0 | ||||||
| 2021-02-10 | 2021-02-08 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 2,407,328 | 4,690,153 | ||||||
| 2021-02-05 | 2021-02-03 | 4 | Vojta Deneen | SNSE | Stock Option (Right to Buy) | D | 19.00 | 16,666 | 16,666 | |||||
| 2021-02-05 | 2021-02-03 | 4 | RICKS THOMAS G | SNSE | Stock Option (Right to Buy) | D | 19.00 | 16,666 | 16,666 | |||||
| 2021-02-05 | 2021-02-03 | 4 | Holmen Bob | SNSE | Stock Option (Right to Buy) | D | 19.00 | 16,666 | 16,666 | |||||
| 2021-02-05 | 2021-02-03 | 4 | Peyer James | SNSE | Stock Option (Right to Buy) | I | 19.00 | 16,666 | 16,666 | |||||
| 2021-02-05 | 2021-02-03 | 4 | Fjaellskog Marie-Louise | SNSE | Stock Option (Right to Buy) | D | 19.00 | 79,166 | 79,166 | |||||
| 2021-02-05 | 2021-02-03 | 4 | Hoey Anupama | SNSE | Stock Option (Right to Buy) | D | 19.00 | 83,333 | 83,333 | |||||
| 2021-02-05 | 2021-02-03 | 4 | Colgan Erin | SNSE | Stock Option (Right to Buy) | D | 19.00 | 52,083 | 52,083 | |||||
| 2021-02-05 | 2021-02-03 | 4 | Celebi John | SNSE | Stock Option (Right to Buy) | D | 19.00 | 416,666 | 416,666 | |||||
| 2021-02-05 | 2021-02-03 | 4 | Broder Samuel | SNSE | Stock Option (Right to Buy) | D | 19.00 | 16,666 | 16,666 | |||||
| 2021-02-05 | 2021-02-03 | 4 | Cambrian BioPharma Inc | SNSE | Stock Option (Right to Buy) | D | 19.00 | 16,666 | 16,666 | |||||
| 2021-02-03 | 3 | Pierce Robert Hamilton | SNSE | Common Stock | D | 73,463 | ||||||||
| 2021-02-03 | 3 | Holmen Bob | SNSE | Common Stock | D | 16,666 | ||||||||
| 2021-02-03 | 3 | Peyer James | SNSE | Common Stock | I | 2,282,825 | ||||||||
| 2021-02-03 | 3 | SAMUELI SUSAN | SNSE | Common Stock | D | 64,163 | ||||||||
| 2021-02-03 | 3 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 2,282,825 |
P
Pembelian sekuritas non-derivatif atau derivatif di pasar terbuka atau secara pribadi.
S
Penjualan terbuka atau penjualan pribadi atas sekuritas non-derivatif atau derivatif.
A
Hibah, penghargaan, atau perolehan sekuritas lainnya dari perusahaan (seperti opsi)
C
Konversi turunan
D
Penjualan atau pengalihan sekuritas kembali ke perusahaan.
F
Pembayaran harga pelaksanaan atau kewajiban pajak menggunakan sebagian sekuritas yang diterima dari perusahaan.
G
Pemberian sekuritas oleh atau kepada orang dalam.
K
Swap ekuitas dan transaksi lindung nilai serupa
M
Pelaksanaan atau konversi sekuritas derivatif yang diterima dari perusahaan (seperti opsi)
V
Transaksi yang dilaporkan secara sukarela pada Formulir 4.
J
Lainnya (disertai dengan catatan kaki yang menjelaskan transaksi tersebut)
